Dr Reddys Laboratories Gains 2.13%: 4 Key Technical Shifts Shape Weekly Trend

3 August: Strong Opening with Positive Momentum

Dr Reddys Laboratories Ltd began the week on a positive note, closing at ₹1,169.90, up ₹22.30 or 1.94% from the previous Friday’s close of ₹1,147.60. This gain outpaced the Sensex’s 0.82% rise to 36,985.17. The stock traded within a range of ₹1,161.05 to ₹1,175.00, signalling early optimism. Volume was robust at 144,793 shares, indicating active participation. Despite this, the stock remained well below its 52-week high of ₹1,414.40, suggesting room for further upside if momentum sustains.

4 August: Shift from Sideways to Mildly Bearish Technical Momentum

On 4 August, the stock retreated slightly to ₹1,160.65, down 0.79% on subdued volume of 44,527 shares. This decline coincided with a technical momentum shift from a sideways trend to a mildly bearish stance. Key indicators such as the weekly MACD turned bearish, while the monthly MACD remained mildly bearish, signalling weakening medium-term momentum. The RSI hovered neutrally, offering no clear directional bias. Bollinger Bands suggested mild downside pressure, with the stock testing lower volatility bands. Daily moving averages showed mild bullishness, indicating short-term support despite the broader caution.

5 August: Mixed Signals Amid Mild Recovery

The stock rebounded to ₹1,174.00, gaining 1.15% on moderate volume of 53,981 shares. This recovery aligned with a technical momentum shift back towards mild bullishness on daily moving averages, though weekly and monthly indicators remained cautious. The MACD on weekly charts stayed bearish, while monthly MACD was mildly bearish. RSI remained neutral, and Bollinger Bands continued to indicate mild bearish pressure. The Know Sure Thing (KST) indicator showed bearishness weekly but bullishness monthly, reflecting a divergence in momentum across timeframes. The stock’s performance slightly outpaced the Sensex’s 0.38% gain to 37,074.66.

6 August: Death Cross Formation Signals Bearish Trend

On 6 August, Dr Reddys Laboratories Ltd closed marginally higher at ₹1,175.00 (+0.09%) on lower volume of 35,929 shares. However, the day was marked by the formation of a Death Cross, where the 50-day moving average crossed below the 200-day moving average. This technical event is widely regarded as a bearish signal, indicating potential sustained downward pressure. Supporting this, the daily moving averages turned firmly bearish, and the weekly MACD remained negative. Bollinger Bands on weekly and monthly charts confirmed mild bearishness, while the RSI showed no oversold condition yet. The stock’s one-month return of -14.16% starkly contrasted with the Sensex’s 0.86% gain, underscoring the stock’s recent underperformance.

7 August: Bearish Technical Shift Amid Mixed Momentum Signals

The week closed on 7 August with the stock slightly retreating to ₹1,172.00, down 0.26% from the previous day, on increased volume of 65,188 shares. Despite the marginal decline, the overall technical stance shifted from mildly bearish to bearish. The MACD on weekly charts remained bearish, while monthly MACD was mildly bearish. Daily moving averages confirmed a bearish trend, with the stock trading below key moving averages. Bollinger Bands indicated increased volatility with a downward bias. The KST indicator remained bearish weekly but bullish monthly, reflecting ongoing uncertainty. Dow Theory assessments were mildly bearish weekly and neutral monthly. On-Balance Volume (OBV) was bearish weekly, suggesting selling pressure. Relative to the Sensex’s 0.21% decline, Dr Reddys Laboratories Ltd showed a slightly weaker performance.

Key Takeaways

Dr Reddys Laboratories Ltd’s week was defined by a series of technical shifts that highlight a cautious and complex outlook. The stock outperformed the Sensex with a 2.13% weekly gain versus the benchmark’s 1.13%, yet underlying momentum indicators reveal growing bearish pressures. The formation of the Death Cross on 6 August is a significant bearish signal, supported by bearish MACD and OBV readings on weekly charts. Mixed signals from the KST and neutral RSI readings suggest potential for short-term consolidation but limited conviction for a sustained rally.

The stock’s relative underperformance over the past month and year, combined with a Mojo Grade downgrade to Sell and a current Mojo Score of 30.0, underscores the need for prudence. Investors should monitor critical support near the 52-week low of ₹1,080.05 and watch for any reversal in momentum indicators before considering increased exposure. The Pharmaceuticals & Biotechnology sector’s ongoing regulatory and competitive challenges add further complexity to the stock’s outlook.

Conclusion

In summary, Dr Reddys Laboratories Ltd’s week was marked by a modest price gain but significant technical deterioration. The shift from sideways to bearish momentum, culminating in the Death Cross formation, signals increased downside risk in the medium term. While short-term daily moving averages show occasional mild bullishness, the prevailing technical landscape advises caution amid mixed momentum signals and sector headwinds. Investors and traders should closely watch evolving technical indicators and sector developments to navigate this uncertain environment effectively.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →